Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 8/20 | 0.62 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.43 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11506429 | 0.96 | PLA2G2C (0.59) | PLA2G2CPLA2G2ADPP7DPP4DPP8 | |
| SCHEMBL28751562 | 0.94 | PLA2G2C (0.67) | PLA2G2CPLA2G2ACA2 | |
| SCHEMBL2666554 | 0.94 | PLA2G2C (0.67) | PLA2G2CPLA2G2ACA2 | |
| SCHEMBL13715798 | 0.91 | PLA2G2C (0.59) | PLA2G2CPLA2G2ACA1CA2 | |
| SCHEMBL11606057 | 0.91 | PLA2G2C (0.64) | PLA2G2CPLA2G2A | |
| SCHEMBL19271824 | 0.91 | PLA2G2C (0.64) | PLA2G2CPLA2G2A | |
| SCHEMBL19271786 | 0.91 | PLA2G2C (0.64) | PLA2G2CPLA2G2A | |
| SCHEMBL6940595 | 0.91 | PLA2G2C (0.64) | PLA2G2CPLA2G2A | |
| SCHEMBL30887481 | 0.91 | PLA2G2C (0.64) | PLA2G2CPLA2G2A | |
| SCHEMBL10576657 | 0.91 | PLA2G2C (0.64) | PLA2G2CPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379238-A1 | FAVORABLE MODULATION OF HEALTH-RELATED QUALITY OF LIFE AND HEALTH-RELATED QUALITY-ADJUSTED TIME-TO-PROGRESSION OF DISEASE IN PATIENTS WITH PROSTATE CANCER | Abbott Laboratories (US) | 2004-01-14 | — | — | EP | disclosed |
| US-20030092757-A1 | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer | ABBOTT LABORATORIES | 2003-05-15 | — | — | US | disclosed |
| WO-2002085351-A1 | FAVORABLE MODULATION OF HEALTH-RELATED QUALITY OF LIFE AND HEALTH-RELATED QUALITY-ADJUSTED TIME-TO-PROGRESSION OF DISEASE IN PATIENTS WITH PROSTATE CANCER | ABBOTT LABORATORIES (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092757-A1 | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer | KLK3, ACP3, BPHL | PLA2G2C 857/4885PLA2G2A 652/4885DPP7 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.